Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma

Cheng-Cao Sun1,2,*, Qun Zhou3,*, Wei Hu3,*, Shu-Jun Li4,*, Feng Zhang3, Zhen-Long Chen4, Guang Li5, Zhuo-Yue Bi6, Yong-Yi Bi3, Feng-Yun Gong7, Tao Bo7, Zhan-Peng Yuan3, Wei-Dong Hu8, Bo-Tao Zhan9, Qian Zhang10, Qi-Zhu Tang11 and De-Jia Li3

1Department of Preventive Medicine, School of Health Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
2Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of Occupational and Environmental Health, School of Health Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
4Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, Wuhan, Hubei 430022, P.R. China
5Department of Oncology, Wuhan Pu-Ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430034, P.R. China
6Hubei Provincial Key Laboratory for Applied Toxicology (Hubei Provincial Academy for Preventive Medicine), Wuhan, Hubei 430079, P.R. China
7Department of Infectious Diseases, Wuhan Medical Treatment Center, Wuhan, Hubei 430023, P.R. China
8Department of Oncology, ZhongNan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
9Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 430021, P.R. China
10Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
11Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China

*Equal contribution

Correspondence to: Cheng-Cao Sun, De-Jia Li, Qi-Zhu Tang; email: chengcaosun@whu.edu.cn, lodjlwhu@sina.com, qztang@whu.edu.cn

Keywords: E2F translational factors, lung carcinoma, prognosis, Kaplan-Meier plot

Received: March 22, 2018 Accepted: April 28, 2018 Published: May 11, 2018

Copyright: Sun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

E2F is a group of genes that encode a family of transcription factors (TFs) in higher eukaryotes and participate in cell cycle regulation and DNA synthesis in mammalian cells. Evidence from cell lines, mouse models, and human tissues indicates that TFs are implicated in lung cancer (LC) tumorigenesis. However, the diverse expression patterns and prognostic values of eight E2Fs have yet to be elucidated. In the current study, we examined the transcriptional and survival data of E2Fs in patients with LC from ONCOMINE, GEPIA, Kaplan–Meier Plotter, and cBioPortal databases. We found that the expression levels of E2F1/2/3/5/6/7/8 were higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in lung tissues, whereas the expression level of E2F4 was lower in the former than in the latter. The expression levels of E2F2/4/5/7/8 were correlated with
advanced tumor stage. Survival analysis using the Kaplan–Meier Plotter database revealed that the high transcription levels of E2F1/2/4/5/7/8 were associated with low relapse-free survival (RFS) in all of the patients with LC. Conversely, high E2F3/6 levels predicted high RFS in these patients. This study implied that E2F3/6/7 are potential targets of precision therapy for patients with LC and that E2F1/2/4/5/8 are new biomarkers for the prognosis of LC.

INTRODUCTION

E2Fs, a group of genes that encode a family of transcription factors (TFs) in higher eukaryotes, are generally subdivided into two groups based on functions: transcriptional activators (E2F1, E2F2, and E2F3a) and transcriptional repressors (E2F3b and E2F4-8) [1]. E2F family members play a major role in cell cycle regulation and DNA synthesis in mammalian cells [2]. The expression of E2F activators is deregulated in several human malignancies, including bladder cancer [3], breast cancer [4], ovarian cancer [5], prostate cancer [5], gastrointestinal cancer [6], and lung cancer [7,8].

Lung cancer (LC) is a common malignancy and the leading cause of cancer-related deaths worldwide [9-11]. This malignancy is divided into two main histological types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma and accounts for approximately 85% of all LCs [12-15]. Despite considerable advancements in diagnostic and treatment methods, the 5-year overall survival rate of LC remains less than 15% [16,17]. Hence, prognostic markers and potential drug targets should be identified to enhance prognosis and individualized treatments.

Up to date, eight E2F factors have been identified in mammalian cells and numbered in the order of their discovery (E2F1, E2F2, E2F3, E2F4, E2F5, E2F6, E2F7, and E2F8) [4,6]. Among these factors, E2F1, E2F2, E2F3, and E2F8 are considered oncogenes in LC development, as indicated by evidence in LC cell lines, animal models, and primary human tissues [7,8,18-20]. Huang et al. reported that E2F1 gene expression is correlated with TS and Survivin gene expression and tumor proliferation. During the progression of NSCLC, E2F1 overexpression can result in increased aggressiveness, high proliferation rate, and enhanced chemoresistance in tumors [7]. Park et al. [19] showed that E2F8 is overexpressed in LC tumors compared with that in normal lung tissues, and the depletion of E2F8 inhibits LC cell proliferation and tumor growth by suppressing UHRF1 expression through UHRF1 promoter binding. However, the underlying mechanism by which E2Fs are activated or depressed and the distinct functions of the E2F factors in LC have yet to be fully elucidated.

The dysregulated expression level of E2F factors and their relationship with clinicopathological features and prognosis have been partly reported in human LC. To the best of our knowledge, bioinformatics analysis has yet been applied to explore the role of E2Fs in LC. RNA and DNA research, an essential component of biological and biomedical studies, have been revolutionized with the development of microarray technology [21]. On the basis of the analyses of thousands of gene expression or variation in copy numbers published online, we analyzed the expression and mutations of different E2F factors in patients with LC in detail to determine the expression patterns, potential functions, and distinct prognostic values of TFs in LC.

RESULTS

Transcriptional levels of E2Fs in patients with LC

Eight E2F factors have been identified in mammalian cells. We compared the transcriptional levels of E2Fs in cancers with those in normal samples by using ONCOMINE databases (Figure 1). The mRNA expression levels of E2F8 were significantly upregulated in patients with LC in five datasets. In Hou’s dataset [22], E2F8 is overexpressed compared with that in the normal samples in all of the LC types: lung adenocarcinoma with a fold change of 3.659, large-cell lung carcinoma with a fold change of 4.707, and squamous cell lung carcinoma with a fold change of 2.48 (Table 1). In Su’s dataset [23], E2F8 is also overexpressed in lung adenocarcinoma with a fold change of 4.707, and squamous cell lung carcinoma with a fold change of 2.48 (Table 1). In Su’s dataset [23], E2F8 is also overexpressed in lung adenocarcinoma with a fold change of 5.779. Bhattacharjee [24] showed another mRNA expression factor with increased expression; that is, E2F3 has a fold change of 3.002 in patients with lung adenocarcinoma and a fold change of 3.002 in patients with SCLC compared with that in patients with normal lung tissues (Table 1). E2F3 overexpression is also found in large-cell lung carcinoma with a fold change of 2.338 in Hou’s dataset [22] and in SCLC with a fold change of 2.006 in Talbot’s dataset [25].
Table 1. The significant changes of E2Fs expression in transcription level between different types of lung cancer and lung tissues (ONCOMINE database).

| Types of lung cancer vs. lung | Fold change | P value     | t-test   | Ref                  |
|------------------------------|-------------|-------------|---------|----------------------|
| E2F1 Lung Adenocarcinoma vs. Normal | 2.142       | 2.79E-06    | 6.168   | Garber [26]          |
| E2F2 Lung Adenocarcinoma vs. Normal | 2.084       | 2.21E-05    | 5.658   | Garber [26]          |
| E2F3 Squamous Cell Lung Carcinoma vs. Normal | 2.066       | 1.66E-13    | 9.337   | Talbot [25]          |
| E2F4 E2F1 Lung Adenocarcinoma vs. Normal | 2.238       | 1.12E-14    | 9.707   | Selamat [27]         |
| E2F5 Squamous Cell Lung Carcinoma vs. Normal | 3.002       | 7.14E-05    | 4.733   | Bhattacharjee [24]   |
| E2F6 Lung Adenocarcinoma vs. Normal | 3.919       | 7.16E-06    | 5.632   | Bhattacharjee [24]   |
| E2F7 Squamous Cell Lung Carcinoma vs. Normal | 2.338       | 4.91E-06    | 5.904   | Hou [22]             |
| E2F8 Lung Adenocarcinoma vs. Normal | 4.085       | 9.91E-05    | 4.576   | Bhattacharjee [24]   |
| E2F9 Squamous Cell Lung Carcinoma vs. Normal | 2.208       | 1.51E-06    | 5.984   | Stearman [28]        |
| E2F10 NA NA NA NA NA NA NA NA NA | NA | NA | NA | NA |
The mRNA expression levels of E2F1, E2F2, E2F5, and E2F7 were upregulated in patients with LC. The transcription levels of E2F1 in lung adenocarcinoma and squamous cell lung carcinoma are higher than those in lung tissues, and their fold changes are 2.142 and 2.084, respectively [26]. In Selamat’s dataset [27], the mRNA expression of E2F2 in lung adenocarcinoma increases with a fold change of 2.238 ($p < 0.005$). A similar trend is showed in E2F5 in Bhattacharjee’s [24] and Stearman’s datasets [28]. E2F5 is significantly upregulated in lung adenocarcinoma, with fold changes of 4.085 and 2.208 in Bhattacharjee’s dataset [24] and Stearman’s dataset [28], respectively (Table 1). The transcriptional levels of E2F7 in squamous cell lung carcinoma (fold change = 7.296) and in large-cell lung carcinoma (with fold change = 4.243) significantly differ from those in the normal samples in Hou’s dataset (Table 1) [22].

Figure 2. The expression of E2Fs in LC (GEPIA).
Figure 3. Correlation between E2Fs expression and tumor stage in LC patients (GEPIA).

Figure 4. The expression of E2Fs in LC (IHC).
Relationship between the mRNA levels of E2Fs and the clinicopathological parameters of patients with LC

Using GEPIA (Gene Expression Profiling Interactive Analysis) dataset (http://gepia.cancer-pku.cn/), we compared the mRNA expression of E2F factors between LC and lung tissues. The results indicated that the expression levels of E2F1, E2F2, E2F3, E2F5, E2F6, E2F7, and E2F8 were higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in lung tissues, whereas the expression level of E2F4 was lower in the former than in the latter (Figure 2). We also analyzed the expression of E2Fs with tumor stage for lung adenocarcinoma and squamous cell lung carcinoma. E2F2, E2F4, E2F5, E2F7, and E2F8 groups significantly varied, whereas E2F1, E2F3, and E2F6 groups did not significantly differ (Figure 3).

We performed IHC to test E2F proteins expression in LC tissues and their counterparts and to examine the expression of E2Fs in LC. We found that E2F1, E2F2, E2F7, and E2F8 proteins were more highly expressed in the LC tissues than in the normal lung tissues (Figure 4).

Association of the increased mRNA expression of E2F1/2/4/5/7/8 and the decreased mRNA expression of E2F3/6 with the improved prognosis of patients with LC

We further explored the critical efficiency of E2Fs in the survival of patients with NSCLC. Kaplan–Meier Plotter tools were used to analyze the correlation between the mRNA levels of E2Fs and the survival of patients with NSCLC in 2437 lung tumors by using publicly available datasets (2015 version) (http://kmplot.com/analysis/index.php?p=service&cancer=lung). The Kaplan–Meier curve and log-rank test analyses revealed that the increased E2F1/2/4/5/7/8 mRNA levels and the decreased E2F3/6 mRNA levels were significantly associated with the overall survival (OS), progression-free survival (FP),

Figure 5. The prognostic value of mRNA level of E2F factors in LC patients (Kaplan-Meier plotter).
and post-progression survival (PPS) ($p < 0.05$) (Figure 5) of all of the patients with LC. The patients with LC with high mRNA levels of the E2F1/2/4/5/7/8 factors or low mRNA levels of E2F3/6 were predicted to have high OS, FP, and PPS.

**Predicted functions and pathways of the changes in E2F factors and their frequently altered neighbor genes in patients with LC**

We analyzed the E2F alterations, correlations, and networks by using the cBioPortal online tool for lung adenocarcinoma (TCGA, Provisional). E2Fs were altered in 257 samples out of 522 patients with lung adenocarcinoma (49%). Two or more alterations were detected in almost half of the samples (128 samples) (Figure 6A). We also calculated the correlations of E2Fs with each other by analyzing their mRNA expression (RNA Seq V2 RSEM) via the cBioPortal online tool for lung adenocarcinoma (TCGA, Provisional), and Pearson’s correction was included. The results indicated significant and positive correlations in the following E2Fs: E2F1 with E2F2, E2F7, and E2F8; E2F2 with E2F1, E2F3, and E2F8; E2F3 with E2F2; E2F7 with E2F1 and E2F8; and E2F8 with E2F1, E2F2, and E2F7 (Figure 6B). We then constructed the network for E2Fs and the 50 most frequently altered neighbor genes. The results showed that the cell cycle-related genes, including CDK2, CDK4, CCNE1, CCNE2, CDKN1B, and CDKN2A, were closely associated with E2F alterations (Figure 6C).

The functions of E2Fs and the genes significantly associated with E2F alterations were predicted by analyzing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) in the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/summary.jsp). GO enrichment

![Figure 6. E2F genes expression and mutation analysis in lung adenocarcinoma (cBioPortal).](image-url)
analysis predicted the functional roles of target host genes on the basis of three aspects, including biological processes, cellular components, and molecular functions. We found that GO:0007049 (cell cycle), GO:0000082 (G1/S transition of mitotic cell cycle), GO:0000122 (negative regulation of transcription from RNA polymerase II promoter), and GO:0045944 (positive regulation of transcription from RNA polymerase II promoter) were significantly regulated by the E2F alterations in lung adenocarcinoma (Figure 7A). GO:0005667 (TF complex), GO:0000307 (cyclin-dependent protein kinase holoenzyme complex), GO:0004693 (cyclin-dependent protein serine/threonine kinase activity), and GO:0004861 (cyclin-dependent protein serine/threonine kinase inhibitor activity) were also significantly controlled by these E2F alterations (Figures 7B and C). They are well-known genes associated with cell cycle.

KEGG analysis can define the pathways related to the functions of E2F alterations and the frequently altered neighbor genes. Fifteen pathways related to the functions of E2F alterations in lung adenocarcinoma were found through KEGG analysis (Figure 8). Among these pathways, ptr05223:NSCLC, ptr05222:SCLC, ptr05200:pathways in cancer, ptr04151:PI3K–Akt signaling pathway, ptr04310:Wnt signaling pathway, and ptr04310:Notch signaling pathway were involved in the tumorigenesis and pathogenesis of lung adenocarcinoma (Figures 9A and B).
Figure 9. Non-small cell lung cancer and Small cell lung cancer signal pathways regulated by the E2Fs alteration in lung adenocarcinoma (cBioPortal).
DISCUSSION

E2F factors dysregulation has been reported in many cancers [2,29-31]. Although the role of E2F activators in the tumorigenesis and prognosis of several cancers has been partially confirmed [7,18,19], further bioinformatics analysis of LC has yet to be performed. The present study is the first time to explore the mRNA expression and prognostic (OS, FP, and PPS) values of different E2F factors in LC. We hope that our findings will contribute to available knowledge, improve treatment designs, and enhance the accuracy of prognosis for patients with LC.

Among the E2Fs, E2F1 is the most studied in LC [32-38]. E2F1 overexpression contributes to the development of LC, and this role is enhanced by the deregulated pRb-p53-DM2 circuitry [39]. E2F1 promotes EMT by regulating ZEB2 in SCLC [38]. In LC, some long noncoding RNAs (lncRNAs) and miRNAs perform their functions by regulating E2F1 [35,36]. E2F1 is also overexpressed in LC samples and involved in largazole-mediated cell cycle arrest at the G1 phase [34]. In our study, ONCOMINE datasets and TCGA datasets revealed that the expression of E2F1 was higher in human LC than in normal tissues. However, E2F1 expression was not correlated with the clinical characteristics of the patients with LC. Using the Kaplan–Meier Plotter, we determined the prognostic value of E2F1 in patients with LC. A high E2F1 expression was significantly associated with poor OS, FP, and PPS in all of the patients with LC followed up for 200 months.

E2F2 is a tumor activator in NSCLC and an independent indicator of OS in patients with NSCLC [18]. Feliciano et al. [40] reported that miR-99a represses EMT in vivo by inhibiting E2F2, prevents stemness features, and consequently decreases the number of cancer stem cells in LC. In our report, the expression of E2F2 in LC tissues was higher than that in normal tissues. We also demonstrated that E2F2 expression was significantly correlated with tumor stage in patients with LC. A high E2F2 expression was significantly correlated with poor OS, FP, and PPS in all of the patients with LC.

E2F3 overexpression is an oncogenic event during human LUAD and LUSC in patients with LC [41]. Trikha et al. [42] demonstrated that E2F3 participates as a key TF in tumor-associated macrophages and influences tumor microenvironment and lung cell metastasis. Interestingly, the lncRNA NEAT1 promotes NSCLC progression by acting as a ceRNA for miR-377-3p and then upregulating E2F3 [43]. Blood mRNA levels of E2F3 are significantly higher in patients with LC than in patients with benign lung diseases or healthy subjects, suggesting that the blood mRNA level of E2F3 is a sensitive diagnostic marker for LC [44]. In our report, we demonstrated that the expression of E2F3 in LC tissues was higher than that in normal tissues, but this expression was not correlated with tumor stage in patients with LC. But to our surprise, a low E2F3 expression was significantly correlated with poor OS, FP, and PPS in all of the patients with LC, which seemed inconsistent with the role of E2F3 as an oncogene.

E2F4, a member of the E2F family of TFs, is abundant in non-proliferating and differentiated cells, and TFs play important roles in the suppression of proliferation-associated genes [45]. E2F4 is a transcription repressor that inhibits cell proliferation and primarily mediates the anti-proliferative activity of capsaicin; the E2F4/p130 pathway has been implicated in the growth and progression of LC [46]. E2F4−/− mice have defects in small airway epithelial cells, suggesting the role of this protein in lung development [47]. Bankovic et al. [48] studied genomic instability in patients with NSCLC through DNA fingerprinting and discovered that E2F4 is among the genes responsible for growth and metastasis of NSCLC. In our report, we demonstrated that the expression of E2F4 was lower in LC tissues than in normal tissues, but this expression was markedly correlated with tumor stage in patients with LC. Interestingly, a high E2F4 expression was significantly correlated with poor OS, FP, and PPS in all of the patients with LC. However, this finding seemed inconsistent with the role of E2F4 as a tumor suppressor.

E2F5 is found highly expressed in several tumors, such as glioblastoma[49], and prostate cancer [50]. But its expression and prognosis role in LC have not been reported. In this report, we demonstrated that the expression of E2F5 in LC tissues was higher than that in normal tissues, but this expression was markedly correlated with tumor stage in patients with LC. A higher E2F5 expression was significantly correlated with poor OS, FP, and PPS in all of the patients with LC.

E2F6 is highly expressed in NSCLC, and miR-424 can inhibit the proliferation and migration abilities of A549 cells by negatively regulating the expression of E2F6 [50]. E2F6 is also upregulated in NSCLC blood samples [51], indicating that E2F6 possesses an oncogenic feature in LC. However, the prognostic role of E2F6 in LC has yet to be investigated. In this report, we demonstrated that the expression of E2F6 in LC tissues was higher than that in normal tissues, but this
expression was not correlated with tumor stage in patients with LC. A higher E2F6 expression was significantly correlated with poor OS, FP, and PPS in all of the patients with LC.

E2F7 and E2F8 function as transcriptional repressors [51]. They also likely serve as activators. E2F7/8 are shown to be activators of transcription; E2F8 binds to and activates the cyclin D1 promoter in a dominantly negative manner by blocking other E2Fs [52]. E2F7/8 directly bind to and stimulate the VEGFA promoter by cooperating with HIF1 [53]. ChIP-sequencing analysis revealed that E2F8 strongly binds to the promoter of UHRF1, and the identified sequence helps activate the promoter, showing that E2F8 may bind to and regulate its target genes, including UHRF1 [19]. E2F8 is also upregulated in LC, and si-E2F8 significantly represses tumor growth in vivo [55]. In the present study, E2F7 and E2F8 were significantly overexpressed in LC tissues, and their expression levels were markedly correlated with the tumor stage of the patients with LC. Interestingly, high E2F7/8 expression was significantly correlated with poor OS, FP, and PPS in all of the patients with LC, indicating the oncogenic role of TFs in LC.

In this study, we systemically analyzed the expression and prognostic value of E2Fs in LC and provided a thorough understanding of the heterogeneity and complexity of the molecular biological properties of LC. Our results indicated that the increased expression of E2F1/2/8 in LC tissues might play an important role in LC oncogenesis. High E2F1/2/7/8 expression could also serve as a molecular marker to identify high-risk subgroups of patients with LC. Our findings suggested that E2F1/2/5/8 were potential therapeutic targets for LC, and transcriptional E2F3/6/7 were potential prognostic markers for the improvement of LC survival and prognostic accuracy.

**MATERIALS AND METHODS**

**Ethics statement**

This study was approved by the Academic Committee of Wuhan University, and conducted according to the principles expressed in the Declaration of Helsinki. All the datasets were retrieved from the publishing literature, so it was confirmed that all written informed consent was obtained.

**ONCOMINE analysis**

ONCOMINE gene expression array datasets (www.oncomine.org), an online cancer microarray database, was used to analyze the transcription levels of E2Fs in different cancers. The mRNA expressions of E2Fs in clinical cancer specimens were compared with that in normal controls, using a Students’ t-test to generate a p value. The cut-off of p value and fold change were defined as 0.01 and 2, respectively.

**GEPIA (Gene Expression Profiling Interactive Analysis) dataset**

GEPIA is a newly developed interactive web server for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects, using a standard processing pipeline. GEPIA provides customizable functions such as tumor/normal differential expression analysis, profiling according to cancer types or pathological stages, patient survival analysis, similar gene detection, correlation analysis and dimensionality reduction analysis [54].

**The Kaplan-Meier plotter**

The prognostic value of E2Fs mRNA expression was evaluated using an online database, Kaplan-Meier Plotter (www.kmplot.com) [55], which contained gene expression data and survival information of 2,437 clinical lung cancer patients (http://kmplot.com/analysis/index.php?p=service&cancer=lung). To analyze the overall survival (OS), progression-free survival (FP), and post progression survival (PPS) of patients with lung cancer, patient samples were split into two groups by median expression (high vs. low expression) and assessed by a Kaplan-Meier survival plot, with the hazard ratio (HR) with 95% confidence intervals (CI) and logrank p value. Only the JetSet best probe set of E2Fs were chosen to obtain Kaplan-Meier plots in which the Number-at-risk is indicated below the main plot.

**TCGA data and cBioPortal**

The Cancer Genome Atlas had both sequencing and pathological data on 30 different cancers [56]. The lung adenocarcinoma (TCGA, Provisional) dataset including data from 522 cases with pathology reports was selected for further analyses of E2Fs using cBioPortal (http://www.cbioportal.org/index.do?session_id=5a37ba8e498eb8b3d562421fb). The genomic profiles included mutations, putative copy-number alterations (CNA) from GISTIC, mRNA expression z-scores (RNA Seq V2 RSEM) and protein expression Z-scores (RPPA). Co-expression and network was calculated according to the cBioPortal's online instruction.
Immunohistochemistry

3-μm tumor sections were incubated with commercial rabbit polyclonal antibodies against E2F1 (Santa Cruz), E2F2 (Santa Cruz), E2F3 (Santa Cruz), E2F4 (Santa Cruz), E2F5 (Santa Cruz), E2F6 (Santa Cruz), E2F7 (Santa Cruz), E2F8 (Santa Cruz) at 1/100 dilution overnight at 4°C. Then, the sections were conjugated with horseradish peroxidase (HRP) antibody (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature for 2 h, then covered by DAB (Vector Laboratories, Burlingame, CA), and slides were mounted with Vectashield mounting medium (Vector Laboratories). Subsequently, all fields were observed under light microscopy (Olympus 600 auto-biochemical analyzer, Tokyo, Japan). Control experiments without primary antibody demonstrated that the signals observed were specific.

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

FUNDING

This study is funded by the Fundamental Research Funds for the Central Universities (No. 2015305020202, 2042018k0025) to Cheng-Cao Sun, China Postdoctoral Science Foundation (No. 2017M620340) to Cheng-Cao Sun, National Postdoctoral Program for Innovative Talents (No. BX201700178) to Cheng-Cao Sun. It was also supported by Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan 430065, China (No. OHIC2017Y02) to Cheng-Cao Sun.

REFERENCES

1. Sozzani R, Maggio C, Varotto S, Canova S, Bergounioux C, Albani D, Cellà R. Interplay between Arabidopsis activating factors E2Fb and E2Fa in cell cycle progression and development. Plant Physiol. 2006; 140:1355–66. https://doi.org/10.1104/pp.106.077990

2. Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM, Rempel RE. E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell. 2000; 6:729–35. https://doi.org/10.1016/S1097-2765(00)00071-X

3. Santos M, Martínez-Fernández M, Dueñas M, García-Escudero R, Alfaya B, Villacampa F, Saiz-Ladera C, Costa C, Oteo M, Duarte J, Martín V, Gómez-Rodriguez MJ, Martín ML, et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 2014; 74:6565–77. https://doi.org/10.1158/0008-5472.CAN-14-1218

4. Rennhack J, Andrechek E. Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. Oncoscience. 2015; 2:867–71. https://doi.org/10.18632/oncoscience.259

5. Shackney SE, Chowdhury SA, Schwartz R. A novel subset of human tumors that simultaneously overexpress multiple E2F-responsive genes found in breast, ovarian, and prostate cancers. Cancer Inform. 2014 (Suppl 5); 13:89–100.

6. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999; 81:S35–38. https://doi.org/10.1002/(SICI)1097-0215(19990517)81:4<535::AID-IJC5>3.0.CO;2-4

7. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non-small-cell lung cancer. Clin Cancer Res. 2007; 13:6938–46. https://doi.org/10.1158/1078-0432.CCR-07-1539

8. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, Feber A, Lin D, Gao Y, et al. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer. 2006; 54:155–62. https://doi.org/10.1016/j.lungcan.2006.07.005

9. Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long Intergenic Noncoding RNA 00511 acts as an oncogene in non–small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids. 2016; 5:e385. https://doi.org/10.1038/mtna.2016.94

10. Sun C, Li S, Zhang F, Xi Y, Wang L, Bi Y, Li D. Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget. 2016; 7:51784–814. https://doi.org/10.18632/oncotarget.10108

11. Fang J, Sun CC, Gong C. Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochem Biophys Res Commun. 2016; 478:811–17. https://doi.org/10.1016/j.bbrc.2016.08.030

12. Sun CC, Li SJ, Li DJ. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget. 2016; 7:35960–78. https://doi.org/10.18632/oncotarget.8482
13. Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, Zhang F, Fu Y, Li D. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget. 2016; 7:8341–59. https://doi.org/10.18632/oncotarget.7071

14. Sun CC, Li SJ, Zhang F, Pan JY, Wang L, Yang CL, Xi YY, Li J. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget. 2016; 7:21510–26. https://doi.org/10.18632/oncotarget.7517

15. Yang C, Sun C, Liang X, Xie S, Huang J, Li D. Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer Gene Ther. 2016; 23:90–97. https://doi.org/10.1038/cgt.2016.5

16. Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y, Wang L, Wang S, He Q, Huang J, Xie S, Jiang W, Li D. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 2015; 6:25533–74. https://doi.org/10.18632/oncotarget.4575

17. Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, Li D. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 2015; 6:39756–92. https://doi.org/10.18632/oncotarget.5476

18. Chen L, Yu JH, Lu ZH, Zhang W. E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma. Int J Clin Exp Pathol. 2015; 8:10545–54.

19. Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS. E2F8 as a novel therapeutic target for lung cancer. J Natl Cancer Inst. 2015; 107:djv151. https://doi.org/10.1093/jnci/djv151

20. Jin DH, Kim Y, Lee BB, Han J, Kim HK, Shim YM, Kim DH. Metformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells. Oncotarget. 2017; 8:101509–19. https://doi.org/10.18632/oncotarget.21552

21. Sealfon SC, Chu TT. RNA and DNA microarrays. Methods Mol Biol. 2011; 671:3–34. https://doi.org/10.1007/978-1-59745-551-0_1

22. Hou J, Aerts J, den Hamer B, van Ijken W, den Bakker M, Riegerman P, van der Leest C, van der Spek P, Fokkens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010; 5:e10312. https://doi.org/10.1371/journal.pone.0010312

23. Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH, Huang CY. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics. 2007; 8:140. https://doi.org/10.1186/1471-2164-8-140

24. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001; 98:13790–95. https://doi.org/10.1073/pnas.191502998

25. Talbot SG, Estilo C, Maghami E, Sarkaria IS, Pham DK, O-charoenrat P, Socci ND, Ngiai I, Carlson D, Ghossein R, Viale A, Park BJ, Rusch VW, Singh B. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer Res. 2005; 65:3063–71. https://doi.org/10.1158/0008-5472.CAN-04-1985

26. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, Petersen I. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001; 98:13784–89. https://doi.org/10.1073/pnas.241500798

27. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, Lam S, Gazdar AF, Laird-Offringa IA. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012; 22:1197–211. https://doi.org/10.1101/gr.132662.111

28. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005; 167:1763–75. https://doi.org/10.1016/S0002-9440(10)61257-6

29. Timmers C, Sharma N, Opavsky R, Maiti B, Wu L, Wu J, Orringer D, Trikha P, Saavedra HI, Leone G. E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop. Mol Cell Biol. 2007; 27:65–78. https://doi.org/10.1128/MCB.02147-05

30. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009; 9:785–97. https://doi.org/10.1038/nrc2696
31. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993; 365:349–52. https://doi.org/10.1038/365349a0

32. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non-small-cell lung cancer. Clin Cancer Res. 2007; 13:6938–46. https://doi.org/10.1158/1078-0432.CCR-07-1539

33. Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CY, Yuan H. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 2014; 14:276. https://doi.org/10.1186/1471-2407-14-276

34. Wu LC, Wen ZS, Qiu YT, Chen XQ, Chen HB, Wei MM, Liu Z, Jiang S, Zhou GB. Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells. ACS Med Chem Lett. 2013; 4:921–26. https://doi.org/10.1021/ml400093y

35. Yu L, Fang F, Lu S, Li X, Yang Y, Wang Z. lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1. Cancer Gene Ther. 2017; 24:221–26. https://doi.org/10.1038/cgt.2017.10

36. Tai MC, Kajino T, Nakatochi M, Arima C, Shimada Y, Suzuki M, Miyoshi H, Yatabe Y, Yanagisawa K, Takahashi T. miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis. 2015; 36:1464–73.

37. Danielian PS, Bender Kim CF, Caron AM, Vasile E, Bronson RT, Lees JA. E2F4 is required for normal development of the airway epithelium. Dev Biol. 2007; 305:564–76. https://doi.org/10.1016/j.ydbio.2007.02.037

38. Bankovic J, Stojsic J, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic S, Tanic N. Identification of genes associated with non-small-cell lung cancer promotion and progression. Lung Cancer. 2010; 67:151–59. https://doi.org/10.1016/j.lungcan.2009.04.010

39. Fang DZ, Wang YP, Liu J, Hui XB, Wang XD, Chen X, Liu D. MicroRNA-129-3p suppresses tumor growth by targeting E2F5 in glioblastoma. Eur Rev Med Pharmacol Sci. 2018; 22:1044–50.

40. Li SL, Sui Y, Sun J, Jiang TQ, Dong G. Identification of tumor suppressive role of microRNA-132 and its
target gene in tumorigenesis of prostate cancer. Int J Mol Med. 2018; 41:2429–33.

51. Lammens T, Li J, Leone G, De Veylder L. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol. 2009; 19:111–18. https://doi.org/10.1016/j.tcb.2009.01.002

52. Deng Q, Wang Q, Zong WY, Zheng DL, Wen YX, Wang KS, Teng XM, Zhang X, Huang J, Han ZG. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res. 2010; 70:782–91. https://doi.org/10.1158/0008-5472.CAN-09-3082

53. Weijts BG, Bakker WJ, Cornelissen PW, Liang KH, Schaftenaar FH, Westendorp B, de Wolf CA, Paciejewska M, Scheele CL, Kent L, Leone G, Schulte-Merker S, de Bruin A. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1. EMBO J. 2012; 31:3871–84. https://doi.org/10.1038/emboj.2012.231

54. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45:W98–102. https://doi.org/10.1093/nar/gkx247

55. Győrffy B, Surowiak P, Budczies J, Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8:e82241. https://doi.org/10.1371/journal.pone.0082241

56. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61–70. https://doi.org/10.1038/nature11412